초록 ▼

Use of proanthocyanidins as an active ingredient of a stimulator as a source of arginine and a source of nitric oxide in the treatment of erectile dysfunction. The active ingredient stimulates the endothelial NO-synthase enzyme, which acts as a catalyst for the synthesis of nitric oxide from its sub

Use of proanthocyanidins as an active ingredient of a stimulator as a source of arginine and a source of nitric oxide in the treatment of erectile dysfunction. The active ingredient stimulates the endothelial NO-synthase enzyme, which acts as a catalyst for the synthesis of nitric oxide from its substrate L-arginine or its salts. The nitric oxide in turn activates theguanylyl cyclase, which leads to an increased development of cyclic guanosine monophosphate, which causes relaxation of smooth muscles. Blood vessel diameter may increase. The stimulator may also have Sildenafil or enzymes that inhibit an enzyme phosphodiesterase type5 from reducing an amount of the cyclic guanosine monophosphate. The substrate may be amino acid L-arginine, arginine salts or a dipeptide of arginine and aspartic acid.

대표청구항 ▼

1. A method of relieving symptoms of erectile dysfunction by stimulating nitric oxide (NO) synthase enzyme and releasing nitric oxide, comprising administering both proanthocyanidins and a substrate, which is a source of arginine and, subsequently, of nitric oxide; stimulating an endothelial NO-synt

1. A method of relieving symptoms of erectile dysfunction by stimulating nitric oxide (NO) synthase enzyme and releasing nitric oxide, comprising administering both proanthocyanidins and a substrate, which is a source of arginine and, subsequently, of nitric oxide; stimulating an endothelial NO-synthase enzyme with the proanthocyanidins; and releasing the nitric oxide from the substrate in response to the stimulated endothelial NO-synthase enzyme acting as a catalyst for synthesis of the nitric oxide, the proanthocyanidins and the substrate each being in therapeutically effective amounts to cause a sufficient amount of the nitric oxide to be released from the synthesis to relieve symptoms of erectile dysfunction. 2. The method according to claim 1, wherein the proanthocyanidins are in an amount of 40 to 300 mg. 3. The method according to claim 1, wherein the substrate is in an amount between 200 milligrams and 2 grams, inclusive. 4. The method according to claim 1, wherein the proanthocyanidins and the substrate are administered simultaneously. 5. The method according to claim 4, wherein the proanthocyanidins are in a dosage of 1-1.5 mg/kg and the substrate is in a dosage of 15-40 mg/kg. 6. The method according to claim 1, further comprising providing the proanthocyanidins in a form suitable for oral administration. 7. The method according to claim 1, wherein the stimulating is also carried out at the same time with sildenafil. 8. The method according to claim 1, wherein the stimulating is carried out while inhibiting an enzyme phosphodiesterase type 5 from reducing an amount of cyclic guanosine monophosphate. 9. The method according to claim 1, wherein the stimulating is carried out while preventing a decrease of cyclic guanosine monophosphate. 10. A composition to relieve symptoms of erectile dysfunction, the composition comprising a substrate as a source of arginine and, subsequently, for nitric oxide and a stimulator that includes proanthocyanidins to stimulate an endothelial NO-synthase enzyme, which serves as a catalyst for synthesis of the nitric oxide, the proanthocyanidins and the substrate being in therapeutically effective amounts to cause a sufficient amount of the nitric oxide to be released from the synthesis to relieve symptoms of erectile dysfunction. 11. The composition as in claim 10 in combination with sildenafil as a further active ingredient in a therapeutically effective amount to relieve the symptoms of erectile dysfunction and stimulate the endothelial NO-synthase enzyme. 12. The composition as in claim 10 in further combination with an inhibitor effective to inhibit an enzyme phosphodiesterase type 5 from reducing an amount of cyclic guanosine monophosphate. 13. The composition as in claim 10 in further combination with substances that are effective to prevent a decrease of cyclic guanosine monophosphate. 14. The composition as in claim 10, wherein the proanthocyanidins are in an amount within a range of 40 mg-300 mg, inclusive. 15. The composition as in claim 10, wherein the L-arginine or its salts is in an amount within a range of 200 mg and 2 grams, inclusive. 16. The composition as in claim 10, wherein the proanthocyanidins are in an amount within a range of 40 mg-300 mg, inclusive. 17. The composition as in claim 10, wherein the proanthocyanidins are in dosage of 1-1.5 mg/kg and the L-arginine or its salts are in a dosage of 15-40 mg/kg.